Compare AbbVie Inc (ABBV) vs VICI Properties Inc (VICI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs VICI Properties Inc — how do they compare? AbbVie Inc trades at $254.09 (market cap $449.91B), while VICI Properties Inc trades at $26.28 (market cap $29.48B). The key difference: AbbVie Inc is far larger — about 15.3× VICI Properties Inc's market cap, and VICI Properties Inc pays the higher dividend (6.72%). Which is the better fit depends on your goals.
| ABBV | VICI | |
|---|---|---|
Market Cap | $449.91B | $29.48B |
Sector | Health | Real Estate |
52-Week High | $261.07 | $33.93 |
52-Week Low | $184.85 | $26.09 |
Enterprise Value | $513.38B | $46.70B |
Dividend Yield | 2.72% | 6.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
VICI Properties trades at $26.70, down 1.78% on the day, reflecting a bearish technical trend. The stock shows strong fundamentals with a P/E of 9.14, a net income margin of 76.83%, and consistent earnings beats in recent quarters. Recent news highlights its investment-grade balance sheet and a 6.8% dividend yield, though technical indicators signal caution with a bearish moving average consensus.
The outlook for VICI is positive based on fundamentals, with a consensus price target of $30.67 implying 15% upside. Risks include tenant concentration and market volatility, but the company's stable cash flows and analyst buy ratings (76.9%) support a favorable long-term view for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About VICI Properties Inc
VICI Properties is an S&P 500 experiential real estate investment trust (REIT) that owns one of the largest portfolios of market-leading gaming, hospitality, and entertainment destinations, including Caesars Palace and MGM Grand. It utilizes a long-term, triple-net lease model to provide stable, inflation-protected income, serving as the primary landlord for the 'experience economy' while diversifying into non-gaming sectors like wellness, youth sports, and luxury resorts.
Read more on VICI →
